Overview: Histopathology Small Biopsy TestIntroduction: The Histopathology Small Biopsy Test examines small tissue biopsies to diagnose diseases like cancer, causing lumps or pain. Aligned with 2023 CAP guidelines, it uses microscopy for high specificity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected malignancies or tissue disorders, ensuring accurate pathological assessment.
Other Names: Small Biopsy Histopath Test, Tissue Biopsy Analysis.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: Histopathology began in the 19th century with microscopy advancements. Small biopsy techniques improved in the 2000s, enhancing diagnostic precision.
Purpose: Diagnoses cancer or tissue disorders, guides treatment, and examines tissue morphology in patients with lumps or pain.
Test Parameters: 1. Tissue Morphology
Pretest Condition: No fasting required. Collect tissue biopsy under sterile conditions. Report symptoms like lumps, pain, or weight loss, and list medications or prior biopsies.
Specimen: 0.5-2 cma³ tissue (sterile container). Place in fixative (e.g., formalin) immediately. Transport in a biohazard container within 2 hours.
Sample Stability at Room Temperature: 2 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not frozen
Medical History: Document lumps, pain, weight loss, or history of cancer. Include current medications, prior biopsies, or radiation exposure.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for surgical or oncological intervention.
Procedural Considerations: Uses microscopy to examine tissue morphology. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories, often for cancer diagnosis.
Factors Affecting Result Accuracy: Improper fixation, small sample size, or contamination can affect results. Sampling error may miss malignant areas.
Clinical Significance: Abnormal morphology confirms cancer or other tissue disorders, guiding treatment (e.g., surgery, chemotherapy). Normal results may require repeat biopsy.
Specialist Consultation: Consult a pathologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Immunohistochemistry, molecular testing, or imaging (e.g., CT, MRI) to confirm diagnosis and stage disease.
Test Limitations: Sampling error may miss pathology. Clinical correlation and additional testing are needed.
References: CAP Histopathology Guidelines, 2023; Archives of Pathology, Fletcher CDM, 2022.
